nach oben

01.05.2016 | Commentary

Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?

Erschienen in: PharmacoEconomics | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Excerpt

Although a basic concept of economic theory is that the price of a good depends on demand for it, the health sector is an exception and pharmaceutical pricing is a clear example of ‘market failure’, with drugs considered special ‘merit goods’ rather than common ‘consumer goods’ [1]. From the demand side, patients are not normal consumers; instead, medical doctors decide therapies on their behalf (the so called ‘principal-agent relationship’) and pharmaceutical expenses are mostly funded by ‘third-party payers’ throughout the world [2]. …

Pharmaceutical Pricing Policy in a Global Market. Paris: OECD 2008.

Scherer FM. The Pharmaceutical Industry. Prices and progress. N Engl J Med. 2004;351:927–32. doi:10.1056/NEJMhpr04011.CrossRefPubMed

Competitiveness of the EU Market and Industry for Pharmaceuticals. Brussels: European Commission; 2009.

Porter ME. Competitive strategy: techniques for analyzing industries and competitors. New York: New York Free Press; 1998.

Garattini L, Salvioni F, Scopelliti D, Garattini S. A comparative analysis of the pharmaceutical market in four European countries. Pharmacoeconomics. 1994;6(5):417–23.CrossRefPubMed

Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy. 1998;44(1):73–85.CrossRefPubMed

Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy. 2007;81(1):17–28.CrossRefPubMedPubMedCentral

Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy. 2007;82(3):330–9. doi:10.1016/j.healthpol.2006.11.004.CrossRefPubMed

Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–81. doi:10.1056/NEJMp1011024.CrossRefPubMed

10.

Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: its role, specification and prospects in a newly devolved NHS. CHE Discussion Papers February; 2011.

11.

Garattini L, Casadei G. Health technology assessment: for whom the bell tolls? Eur J Health Econ. 2008;9(4):311–2. doi:10.1007/s10198-008-0113-6.CrossRefPubMed

12.

Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care. 2005;43(7 Suppl):5–14.PubMed

13.

Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Health Care. 2010;26(3):330–3. doi:10.1017/S0266462310000322.CrossRefPubMed

14.

Gregson N, Sparrowhawk K, Mauskopf J, Paul J. Pricing medicines: theory and practice, challenges and opportunities. Nat Rev Drug Discov. 2005;4(2):121–30.CrossRefPubMed

15.

AIFA. The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2013. Available online at: http://www.agenziafarmaco.gov.it/sites/default/files/OsMed_Report13_Eng.pdf. Accessed 12 Dec 2015.

16.

van de Vooren K, Curto A, Freemantle N, Garattini L. Market-access agreements for anti-cancer drugs. J R Soc Med. 2015;108(5):166–70. doi:10.1177/0141076814559626.CrossRefPubMed

17.

Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16:1–3. doi:10.1007/s10198-014-0585-5.CrossRefPubMed

Titel: Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?
Publikationsdatum: 01.05.2016
Erschienen in: PharmacoEconomics / Ausgabe 5/2016
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-015-0377-5

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten